Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in patients with residual breast cancer
NCT01401959Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Sep 2011
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in breast cancer, sponsored by SCRI Development Innovations. Started Sep 2011; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01401959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01401959.